心舒宝片联合尼可地尔治疗冠心病心绞痛的临床研究

目的 观察心舒宝片联合尼可地尔片治疗冠心病心绞痛的临床疗效。方法 选择2021年6月—2022年6月于郑州大学第一附属医院诊治的136例冠心病心绞痛患者为研究对象，按照双色球法将患者分为对照组和治疗组，各为68例。对照组口服尼可地尔片，5mg/次，3次/d。治疗组患者在对照组基础上饭后口服心舒宝片，1～2片/次，2次/d。两组患者均连续治疗3个月。比较两组临床疗效、临床症状、心功能指标、血液流变学指标和氧化应激指标。结果 治疗后，治疗组的总有效率（94.12%）明显高于对照组（76.47%）(P<0.05)。治疗后，两组心绞痛发作次数减少、每次持续时间缩短、日均硝酸甘油用量减少，心排血量（CO）、左心室射血分数（LVEF）、心排血指数（CI）均显著升高，血浆黏度、全血高切黏度、全血低切黏度下降，血清超氧化物歧化酶（SOD）水平升高，血清丙二醛（MDA）水平下降（P<0.05），且治疗组临床症状、心功能指标、血液流变学指标、血清氧化应激指标的改善程度较对照组更大（P<0.05）。结论 心舒宝片联合尼可地尔片治疗冠心病心绞痛，能够明显改善心绞痛症状、血液流变学，减轻氧化应...

Clinical study on Xinshubao Tablets combined with nicorandil in treatment of angina pectoris of coronary heart disease

Objective To observe the clinical effect of Xinshubao Tablets combined with Nicorandil Tablets in treatment of angina pectoris of coronary heart disease. Methods Patients (136 cases) with angina pectoris of coronary heart disease in the First Affiliated Hospital of Zhengzhou University from June 2021 to June 2022 were divided into control and treatment groups according to the bicolor sphere method, and each group had 68 cases. Patients in the control group were po administered with Nicorandil Tablets, 5 mg/time, three times daily. Patients in the treatment group were po administered with Xinshubao Tablets after meals on the basis of the control group, 1-2 tablets/time, twice daily. Patients in two groups were treated for 3 months. The clinical efficacies, the clinical symptoms, cardiac function indicators, hemorheological indicators, and oxidative stress indicators in two groups were compared. Results After treatment, the total effective rate of the treatment group (94.12%) was significantly higher than76.47% of the control group (P < 0.05). After treatment, the frequency of angina pectoris attacks, the duration of angina pectoris attacks, and the daily dosage of nitroglycerin were decreased, CO, LVEF, and CI were significantly increased, the plasma viscosity, whole blood high tangential viscosity, and whole blood low tangential viscosity were decreased, the serum level of SOD increased, but the serum level of MDA decreased in two groups (P < 0.05), and the improvement of clinical indexes in the treatment group was better than those in the control group (P < 0.05). Conclusion Xinshubao Tablets combined with Nicorandil Tablets in the treatment of angina pectoris of coronary heart disease has a good improvement effect in treatment of angina pectoris, can significantly improve angina symptoms, hemorheology, and alleviate oxidative stress symptoms.